Stockholders approve Bioventus' $518M acquisition of Misonix, closing date set


Stockholders approved Bioventus' planned acquisition of Misonix.

The $518 million acquisition, announced in July, is expected to close Oct. 29. The stockholders' votes approved the issuance of shares of Biovenus Class A common stock to the stockholders of Misonix.

"The combination with Misonix creates significant value and provides a deeper global portfolio of pain treatments, restorative therapies and surgical solutions for patients," Bioventus CEO Ken Reali said in an Oct. 26 news release.


Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers